Keloid lesions show increased IL‐4/IL‐13 signaling and respond to Th2‐targeting dupilumab therapy

: Keloids are benign growths representing a disrupted wound healing process involving abnormal collagen proliferation. Keloids are most prevalent in African American (AA)1 and Asian populations,2 and greatly impact quality of life.3 Keloids show high recurrence rates and current therapies (intralesional steroids, bleomycin, surgical excision, etc.) have limited efficacy;4 thus, presenting a high unmet need for better treatments.